Blog

Paolo Tarantino: We review best practices and future perspectives for the identification of patients with HER2-low Breast Cancer

Photo of Paolo Tarantino from X

Apr 16, 2024, 00:17

Paolo Tarantino: We review best practices and future perspectives for the identification of patients with HER2-low Breast Cancer

Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, posted on LinkedIn:

“In our latest article, just published on ESMO Open, we review best practices and future perspectives for the identification of patients with HER2-low Breast Cancer.

Thanks to AstraZeneca for supporting this publication and to H. Earle for bravely sharing with us and the journal readers her personal experience while receiving treatment with T-DXd.

See link here.”

Paolo Tarantino

Source: Paolo Tarantino/LinkedIn

AstraZeneca cancer Dana-Farber Cancer Institute ESMO Open Future Perspectives H. Earle HER2-low Breast Cancer latest article medical journal OncoDaily Oncology Paolo Tarantino Personal Experience T-Dxd

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage